Via Ritzau - din kommunikationsplatform

A stamp found with a metal detector on the Danish island of Tåsinge indicates that the iconic helmet from Sutton Hoo in England could have been made in the South Funen archipelago. The find could change what we know about the power balance in Northern Europe in the 7th century, with Denmark playing a more central role than previously thought.

Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.

null

An international team of scientists successfully drilled a 2,800-meter-long ice core, reaching the bedrock beneath the Antarctic ice sheet. These ice samples are expected to unveil, for the first time, critical details about Earth's climate and atmospheric history, extending beyond 800,000 years ago and showing a continuous record of the history of climate and greenhouse gasses as far back as 1.2 million years, and probably beyond.

55% of Azerbaijani respondents say that the energy transition is a priority, in line with European countries • 64% of Azerbaijani respondents (more than the United Arab Emirates, Saudi Arabia and India) and 53% in Kazakhstan (more than Italy, the United Kingdom, the United States and China itself) consider energy transition crucial to combat climate change • Energy transition training and professional development are crucial issues in both Kazakhstan and Azerbaijan for over 80% of those interviewed, more than in India (71%), USA and Saudi Arabia (75%) • The study covers 12 countries in 4 continents for a total of over 2,000 interviews carried out by IPSOS, an international market research company

From 11 to 22 November 2024, the 29th Conference of the Parties (COP29) to the United Nations Framework Convention on Climate Change (UNFCCC) will take place in Baku, Azerbaijan.

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.

Aachen, Germany, 22 October 2024 – Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025.

Columbus, the global digital consultancy, has been awarded Optimizely’s 2024 ‘Commerce Partner of the Year’ in the United Kingdom & Ireland (UK&I) region. This sparks a second-time-in-a-row recognition, since Columbus also won the award in 2023. The aim of Optimizely's prestigious prize is to acknowledge IT companies’ focus on innovation, partnership devotion, and digitalisation possibilities.

Real-world findings showed that subgroup of patients treated with Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) and with head and neck (H&N) atopic dermatitis (AD) at baseline reported presence of AD in that area in 52.1% of patients after nine months of treatment.(1) As part of one of LEO Pharma’s most extensive scientific programs at EADV to date, the late-breaking presentation examined interim data from the real-world TRACE study of adult AD patients who have been prescribed Adtralza/Adbry for up to nine months.(1) Additional posters presented interim results of the TRACE study on effectiveness of Adtralza/Adbry treatment through various physician and patient reported outcomes such as improvements in Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), itch, sleep disturbance and quality of life.(2,3)

Biotechnological pesticides are a promising alternative to traditional chemical pesticides. But we have limited knowledge of how toxic they are to other organisms in the environment beyond regulatory assessments. A new research centre will now work to provide this knowledge – especially to ensure the EU has a chance of joining the growing market for biotechnological pesticides. As for now, Europe has failed to keep up.

How can a fungus take over a fly's behavior? An international group of researchers with participation from the University of Copenhagen hopes to find out with the help of a new genetic map of a unique fungus that transforms 60-80 percent of the flies in your home into zombies. In the future, the fungus could become both an effective insect repellent and basis for new psychotropic drugs.

Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.

Prize under High Patronage of the President of the German Bundestag endowed with 500,000 € for significant contributions towards safeguarding human and planetary health

London (DNA) - A decline in effective national governance and the "long-term scars" caused by austerity measures and Brexit have stifled economic growth and undermined social cohesion in the United Kingdom, according to a study.

- One million people will be trained with AI within three years - By 2031, 40% of GDP is to be generated with AI - Global giants such as Microsoft, Google, and IBM are at the start

LlamaChat, a popular AI chatbot alternative to ChatGPT, leans left and holds pro-European views. This is demonstrated by a University of Copenhagen study in which researchers tested the model on EU policy issues. However, the researchers also showed how it is possible to change this bias.

Largest industrial hemp deal in U.S. history is a milestone for decarbonization efforts

Som led i Stryhns Gruppens mål om at reducere det totale madspild med 50% og blive klimaneutrale i egen produktion i 2030, har fødevarevirksomheden investeret stort i at bekæmpe produktspild og nedsætte klimabelastningen. En ny tankfarm hos Graasten Salater, har indtil videre nedsat produktspild svarende til 82 tons eller 545.000 tuber remoulade på et år. Når tankfarmen står færdig og har fuld effekt, forventes besparelsen på produktspild at svare til 155 tons, eller over en million tuber remoulade årligt. Siden Stryhns Gruppen i 2018 blev en del af Danmark Mod Madspild, har fødevarevirksomheden arbejdet intensivt på at nedsætte madspild og mindske CO2-udledningen. Indtil videre er det lykkedes at nedsætte færdigvarespildet med 95%, og det totale spild med en tredjedel. En af de helt store investeringer, Stryhns Gruppen har foretaget for at nå målene, er projektet Graasten Go Green: En 600 kvm tankfarm, der opføres som tilbygning til fabrikken i Gråsten, som skal sikre mere ansvarlig p

The launch in Germany through its step-down subsidiary betapharm marks Dr. Reddy's entry into digital therapeutics in Europe. Nerivio® is the first REN (wearable, FDA-cleared, and CE-marked for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years). Nerivio® is worn on the upper arm during treatment and controlled by a smartphone app, making it comfortable and portable. Starting with Germany, followed by Spain and the UK, Dr. Reddy's plans to further increase access to Nerivio® in European countries.